Aminex PLC
18 July 2007
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART OR IN WHOLE IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN
FOR IMMEDIATE RELEASE
18 JULY 2007
Aminex PLC ("Aminex" or "the Company")
Further re: Rights Issue
Placing of 2,705,476 New Ordinary Shares not taken up in the Rights Issue
Further to the announcement issued on 16 July 2007 that Aminex had received
valid acceptances in respect of 14,465,371 New Ordinary Shares, representing
approximately 51.4 per cent. of the New Ordinary Shares offered to Qualifying
Shareholders under the 1 for 6 Rights Issue, the Company announces that Davy has
procured subscribers for 2,705,476 New Ordinary Shares (including the
entitlement of overseas shareholders and fractional entitlements) which were not
validly taken up in the Rights Issue, at a price of Stg£0.21 per New Ordinary
Share. The remaining New Ordinary Shares available under the Rights Issue will
not be issued.
Subscribers for Rights Issue Shares are entitled to 1 New Warrant for every 2
Rights Issue Shares subscribed for so long as they are recorded as the
registered holder of those Rights Issue Shares at Admission on 2 August 2007
(the date on which the Rights Issue Shares and associated New Warrants are
expected to be credited to CREST stock accounts).
The Company has raised gross proceeds of US$29.27m from the Firm Placing and the
Rights Issue (including this Placing).
Following completion of the Rights Issue, the Company has 242,031,747 Ordinary
Shares in issue and 36,526,673 New Warrants in issue.
There are no net proceeds from the sale of these New Ordinary Shares, after
deduction of the Rights Issue Price of Stg£0.20 per share and relevant costs, to
be paid to those shareholders who have not taken up their Rights Issue
entitlements.
Definitions used in the Prospectus dated 23 May 2007 shall have the same
meanings when used in this announcement.
For further information:
Aminex PLC
Brian Hall Tel: +44 (0) 20 7291 3100
Davy
Eugenee Mulhern / Fergal Meegan Tel: +353 (0) 1 679 6363
Bridgewell
Andrew Matharu Tel: + 44 (0) 20 7003 3105
Pelham Public Relations
Archie Berens Tel: +44 (0) 20 7743 6679
Davy Corporate Finance Limited and J&E Davy (collectively ''Davy'') (each of
which is regulated in Ireland by the Irish Financial Services Regulatory
Authority) and Bridgewell Limited (''Bridgewell'') (which is regulated in the UK
by the Financial Services Authority) are acting exclusively for Aminex in
connection with the requirements of the Irish Stock Exchange and the UK Listing
Authority and for no one else and will not be responsible to any other person
for providing the protection afforded to customers of Davy or Bridgewell nor for
providing advice in connection with this announcement.
Participation in the Rights Issue is not and has not been available to
shareholders resident in the United States, Australia, Canada, South Africa or
Japan or any other jurisdiction where it would be unlawful to offer
participation.
This announcement does not constitute, or form part of, an offer of, or the
solicitation of any offer to subscribe for or buy, any of the Ordinary Shares or
Warrants to be issued or sold in connection with the Placing and/or Rights
Issue. Investors should not subscribe for or purchase any securities referred to
in this announcement except on the basis of information in the Prospectus
published by the Company on 23 May 2007 in connection with the Placing and
Rights Issue.
The offer of the Ordinary Shares and Warrants in certain jurisdictions may be
restricted by law and therefore potential investors should inform themselves
about and observe any such restrictions. This announcement is not for
publication or distribution, directly or indirectly, in or into the United
States. This announcement is for information only and does not constitute an
offer or invitation to acquire or dispose of Ordinary Shares or Warrants in the
United States. The Placing and Rights Issue will not be an offer of securities
for sale in the United States. Securities may not be offered or sold in the
United States absent registration or an exemption from registration. The
Ordinary Shares and Warrants have not been and will not be registered under the
US Securities Act of 1933, as amended ('the Securities Act'), or with any
securities regulatory authority of any state or other jurisdiction of the United
States, and may not be offered or sold in the United States, except pursuant to
an exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act. There will be no public offering of Ordinary
Shares or Warrants in Aminex in the United States.
Past performance is no guide to future performance and persons needing advice
should consult an independent financial adviser.
The distribution of this announcement may be restricted by law. No action has
been taken that would permit the possession or distribution of this announcement
in any jurisdiction where action for that purpose is required.
This information is provided by RNS
The company news service from the London Stock Exchange RILFSEDAITLID
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.